NEJM original articles

Guest, this browser only · 425 unread · 0 saved · pick a name · updated Nov 21, 6:10 am

Unread All Saved Clear search

November 12, 2026 Vol. 395 No. 19

Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty Shivakumar S et al. Editorial Aspirin Therapy - Enough after Arthroplasty? saved

Background. Aspirin after an initial short course of rivaroxaban has been shown to be safe and effective for the prevention of venous thromboembolism after total hip or total knee arthroplasty, but uncertainty remains about the use of aspirin alone.

Methods. In this multicenter, double-blind, randomized, controlled trial, we assigned patients to receive once-daily thromboprophylaxis with either 81 mg of aspirin or 10 mg of oral rivaroxaban for the first 5 days after total hip or total knee arthroplasty. All the patients then received further thromboprophylaxis with 81 mg of aspirin daily for 9 additional days after knee arthroplasty and for 30 additional days after hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism, which consisted of either proximal deep-vein thrombosis or pulmonary embolism (primary effectiveness outcome), and for bleeding complications (primary safety outcome). The noninferiority margin for aspirin alone as compared with rivaroxaban-aspirin was 0.7 percentage points.

Results. A total of 5429 patients underwent randomization. Venous thromboembolism developed in 13 of 2718 patients (0.48%) in the aspirin-alone group and in 12 of 2647 patients (0.45%) in the rivaroxaban-aspirin group (risk difference, 0.02 percentage points; 95% confidence interval [CI], -0.34 to 0.39; P<0.001 for noninferiority). Major bleeding or clinically relevant nonmajor bleeding events occurred in 45 of 2718 patients (1.66%) in the aspirin-alone group and in 54 of 2647 patients (2.04%) in the rivaroxaban-aspirin group (risk difference, -0.38%; 95% CI, -1.11 to 0.34).

Conclusions. After total hip and total knee arthroplasty, the use of aspirin alone was not inferior to a strategy of using rivaroxaban followed by aspirin for the prevention of symptomatic venous thromboembolism, with no clinically relevant difference in bleeding events. (Funded by the Canadian Institutes of Health Research; EPCAT III ClinicalTrials.gov number, NCT04075240.).

A note or tag saves the article on its own.

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement Pellegrini VD et al. saved

Background. Studies comparing aspirin with anticoagulants for venous thromboembolism (VTE) prophylaxis after total hip or knee arthroplasty have had conflicting results.

Methods. In a comparative-effectiveness noninferiority trial, we randomly assigned patients undergoing elective hip or knee arthroplasty to receive aspirin (81 mg twice daily), warfarin (to a target international normalized ratio of 2.0), or rivaroxaban (10 mg daily) for 30 days. The composite primary effectiveness outcome (death from any cause or symptomatic VTE) and primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) were evaluated through 6 months in a blinded fashion. The noninferiority margin for the risk difference was 0.69 percentage points.

Results. Among 18,883 participants who had undergone randomization, 15,317 (7214 with hip arthroplasty and 8103 with knee arthroplasty) were included in the primary per-protocol analysis. A primary effectiveness outcome event occurred in 77 of 6090 participants (1.26%) in the aspirin group, in 52 of 4231 (1.23%) in the warfarin group, and in 47 of 4996 (0.94%) in the rivaroxaban group; a primary safety outcome event occurred in 177 (2.91%), 142 (3.36%), and 174 (3.48%), respectively. In pairwise comparisons, 6-month risks of a primary effectiveness outcome event were 1.24% and 0.94% for aspirin versus rivaroxaban (difference, 0.30 percentage points; 95% confidence interval [CI], -0.20 to 0.81); 1.24% and 1.01% for aspirin versus warfarin (difference, 0.23 percentage points; 95% CI, -0.34 to 0.81); and 1.13% and 1.10% for warfarin versus rivaroxaban (difference, 0.03 percentage points; 95% CI, -0.57 to 0.63). Risks of a primary safety outcome event were 3.70% and 3.02% for rivaroxaban versus aspirin (difference, 0.68 percentage points; 95% CI, -0.04 to 1.41); 3.65% and 2.88% for warfarin versus aspirin (difference, 0.77 percentage points; 95% CI, -0.04 to 1.58); and 3.59% and 3.61% for rivaroxaban versus warfarin (difference, -0.02 percentage points; 95% CI, -0.89 to 0.85). Intention-to-treat analyses yielded similar results.

Conclusions. Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).

A note or tag saves the article on its own.

Prasugrel versus Ticagrelor in Acute Coronary Syndromes Omerovic E et al. Editorial The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome saved

Background. Whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with an acute coronary syndrome is uncertain.

Methods. We conducted a registry-based, open-label, stepped-wedge, cluster-randomized trial in Sweden involving adults who had undergone percutaneous coronary intervention for an acute coronary syndrome. Seven regions, grouped into three clusters, switched from ticagrelor to prasugrel as the default P2Y12 inhibitor in a randomized sequence across four 9-month periods between 2021 and 2024. The primary end point was a composite of death from any cause, fatal or nonfatal myocardial infarction, or fatal or nonfatal stroke through 1 year, as ascertained from national registries. In the intention-to-treat analysis, a mixed model adjusted for cluster and calendar time was used to obtain a policy-level estimate.

Results. A total of 17,095 patients were enrolled; 9444 received care under the default ticagrelor policy, and 7651 received care under the default prasugrel policy. The mean (±SD) age of the patients was 69.8±11.5 years, and 36.8% were at least 75 years old; 27.8% of the patients were female. A total of 39.4% presented with ST-segment elevation myocardial infarction (STEMI), 43.7% with non-STEMI, and 16.8% with unstable angina. At 1 year, a primary end-point event had occurred in 11.8% of the patients in the ticagrelor-policy group and in 11.1% of those in the prasugrel-policy group (adjusted odds ratio [prasugrel vs. ticagrelor], 0.90; 95% confidence interval [CI], 0.77 to 1.06), and major bleeding had occurred in 4.4% and 4.2%, respectively (adjusted odds ratio, 0.80; 95% CI, 0.64 to 0.99).

Conclusions. In an unselected population of patients with an acute coronary syndrome who had undergone percutaneous coronary intervention, the risk of ischemic events was not lower with a default prasugrel policy than with a default ticagrelor policy. (Funded by Region Västra Götaland; SWITCH-SWEDEHEART ClinicalTrials.gov number, NCT05183178.).

A note or tag saves the article on its own.

Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial Barratt J et al. saved

Background. In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss. Ravulizumab is a terminal complement inhibitor that prevents formation of C5a and C5b-9.

Methods. In this phase 3 trial, we enrolled adults with IgA nephropathy who had an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area and proteinuria (24-hour urinary protein-to-creatinine ratio [with protein and creatinine both measured in grams] of ≥0.75 or total urinary protein excretion of ≥1.0 g per day), despite standard therapy. Patients were randomly assigned in a 1:1 ratio to receive an intravenous infusion of either ravulizumab or placebo every 8 weeks. In the prespecified interim analysis, the primary efficacy end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34. Safety was also assessed.

Results. In all, 485 patients underwent randomization, with 240 patients assigned to the ravulizumab group and 245 to the placebo group; 352 patients (176 in each group) were included in the interim analysis. In the ravulizumab group, the geometric mean 24-hour urinary protein-to-creatinine ratio at baseline and at week 34 was 1.56 and 0.83, respectively; in the placebo group, it was 1.60 and 1.48, respectively. At week 34, a significant reduction in the geometric mean 24-hour urinary protein-to-creatinine ratio was observed with ravulizumab (-46.6%) as compared with the reduction observed with placebo (-5.6%), corresponding to an adjusted geometric mean 24-hour urinary protein-to-creatinine ratio that was 43.4% (99% confidence interval, 30.1 to 54.2) lower with ravulizumab than with placebo (P<0.001). Adverse events occurred in 69.5% of the patients receiving ravulizumab and in 75.8% of those receiving placebo; serious adverse events occurred in 4.6% and 9.0%, respectively. No meningococcal infections or deaths occurred.

Conclusions. In adults with IgA nephropathy, ravulizumab resulted in a significantly greater reduction in the protein-to-creatinine ratio than placebo at week 34. (Funded by Alexion, AstraZeneca Rare Disease Unit; I CAN ClinicalTrials.gov number, NCT06291376; EU Clinical Trials number, 2023-507851-31-00.).

A note or tag saves the article on its own.

3 Perspectives